Nootropics Added to Standard Dementia Treatment: What the Real-World Data Showed

Abstract

In South Korea several compounds sold elsewhere as supplements are prescription medicines, and doctors routinely add them to standard dementia treatment. That produces something rare: a large body of real-world data on whether the addition helps.

A 2022 study followed 583 patients with mild-to-moderate dementia for a year, comparing cholinesterase inhibitors alone against cholinesterase inhibitors plus a nootropic.

The primary analysis found no difference. The paper's stated conclusion is that the combination showed partial effectiveness on some cognitive domains. This article examines both statements, because the gap between them is instructive.

1.Why This Study Design Is Valuable

Randomised trials answer whether something can work under controlled conditions. Real-world data answer whether it does work as actually prescribed, to actual patients, alongside everything else they are taking.

The second question is often the one that matters and it is rarely asked, because the data are messy and the funding is scarce. Here the Korean prescribing environment made it possible.

The compounds involved are worth naming because of where they sit elsewhere. In Korea, alongside general over-the-counter supplements, certain nootropics require prescriptions, and the most frequently prescribed are choline alfoscerate, Ginkgo biloba extract, acetyl-L-carnitine, nicergoline and oxiracetam.

Choline alfoscerate is alpha-GPC — the compound examined in a recent healthy-volunteer trial we discuss in a companion article. Acetyl-L-carnitine has its own article in this section. The same molecules are prescription medicines in one country and shelf products in another, and this study tests them in the first setting.

2.What Was Done

Patients were narrowed to those with mild-to-moderate dementia, defined by baseline Mini-Mental State Examination scores between 10 and 26, giving 583 individuals.

Cognitive function was assessed at baseline — within 30 days of the first cholinesterase inhibitor prescription — and again at endpoint, 300 to 400 days later. The measure was the MMSE total score together with its six subscales: orientation, immediate recall, attention and calculation, delayed recall, language, and visuospatial construction.

The stated hypothesis was that patients treated with both would show less deterioration over the year than those on cholinesterase inhibitors alone.

3.The Primary Result

A linear mixed-effects model with MMSE total score as the dependent variable revealed no significant treatment-by-time interaction: F equal to 1.48, with 1,581 degrees of freedom and a p-value of 0.224.

The same analysis repeated separately in each of the three dementia types found nothing either. Alzheimer's dementia produced F equal to 2.10 with p at 0.148; vascular dementia F equal to 0.38 with p at 0.540; other dementias F equal to 0.04 with p at 0.906.

Four analyses, four null results. On the outcome the study set out to test, adding a nootropic to standard treatment did not slow cognitive decline over a year in 583 patients.

4.The Conclusion, and the Gap

The paper concludes that the results demonstrated partial effectiveness of nootropics with cholinesterase inhibitors on some cognitive domains in Alzheimer's dementia.

That statement rests on the subscales rather than the total. With six subscales analysed across three dementia types and several drug subgroups, a number of comparisons were made, and some produced differences.

We are not suggesting anything improper — the null primary results are reported clearly and the analyses are visible. But a reader who encounters only the conclusion will carry away something quite different from a reader who reaches the mixed-effects models.

The subgroup sizes make the point concrete. Within Alzheimer's patients receiving combination treatment, the choline alfoscerate group numbered 74, the Ginkgo group 39, and other nootropics 21. Twenty-one patients is not a basis for a claim about a drug class.

This is one of the most common shapes in supplement literature and it is worth learning to recognise: null on the pre-specified outcome, positive on a subscale, and the second sentence is the one that travels.

5.What the Authors Say About the Field

The paper's own framing of the prior evidence is refreshingly unvarnished. The clinical benefits of nootropics in treating cognitive decline are described as either limited or controversial, with some studies showing improvements with choline alfoscerate, Ginkgo, acetyl-L-carnitine and nicergoline, and other studies demonstrating no clinical benefit.

That is an accurate description of the literature, and it matches what we found writing separately about acetyl-L-carnitine and citicoline: a pattern of split results that has persisted for decades without resolving.

6.What This Study Cannot Show

It is observational. Patients were not randomised, so those who received an additional nootropic may have differed systematically from those who did not — in disease severity, in how engaged their physician was, in what else they were doing.

The MMSE is also a blunt instrument, designed for screening rather than for detecting modest change, and a year is a short window in which to observe divergence in dementia progression.

And the population is people with a dementia diagnosis on prescribed cholinesterase inhibitors. Nothing here concerns healthy adults, which is the group buying these compounds in most of the world.

7.How We Read It

The most useful finding is the primary null, and it deserves more attention than the paper's own conclusion gives it. In a substantial real-world population, adding these compounds to established treatment produced no detectable difference in overall cognitive trajectory over a year.

That is worth knowing even for someone with no interest in dementia, because these are the same molecules sold to healthy people on the strength of a mechanism. Where the mechanism has been given its best opportunity — in a population with an established deficit, at prescription doses, under medical supervision — it did not move the primary outcome.

Editorial Comment

MindHeaven® uses none of the compounds studied here, though acetyl-L-carnitine appears in Clarity and is one of the five, and choline alfoscerate is closely related to the CDP-choline we use. We make no claims about any of them.

Dementia is a medical condition and nothing in this article should be read as guidance about its treatment. If cognitive decline is a concern for you or someone close to you, that belongs with a doctor, and the primary finding above is a reason to be sceptical of anything sold as an addition to what they prescribe.